Last reviewed · How we verify
paclitaxel liposome injection plus cisplatin
At a glance
| Generic name | paclitaxel liposome injection plus cisplatin |
|---|---|
| Sponsor | Nanjing Luye Sike Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer (PHASE2)
- Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma (NA)
- Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer (PHASE1)
- A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (PHASE2)
- Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) (PHASE2)
- Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer (PHASE2)
- Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU) (PHASE4)
- Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: